TOP HEADLINES

Featured Story

CSL ties up with Enable Injections to market biologic delivery device

Plasma protein specialist CSL Behring has tied the knot with Ohio devicemaker Enable Injections to use Enable's technology for the delivery of treatments for chronic diseases. The development agreement will give CSL access to market the device.

Eye care company pSivida receives royalty payment, will spend it on pipeline

Eye care company pSivida will use the $25 million milestone payment for the recent FDA approval of sustained-release therapy Iluvien to fund its pipeline.

Microscale fibers may have many drug-delivery uses

Drug delivery researchers are probing the depths of nanotechnology. However, researchers at New York University have shown that the maxim "better is better" can be true in the drug-delivery world as well, due to the development of drug delivering fibers that are the diameter of spider silk.

Harvard team uses stem cells to deliver toxic doses to cancer cells

Researchers at Harvard have programmed stem cells embedded in a tumor to deliver a toxic dose of cytotoxins, killing the cancer cells from the inside.

BDSI aiming to develop injectable buprenorphine

BioDelivery Sciences International is partnering with Evonik to develop a formulation of buprenorphine that can be subcutaneously injected and provide continuous therapy for 30 days. BDSI will pursue an approval for opioid dependence in about three years, but also aims to develop a product for chronic pain in patients requiring continuous opioid therapy.

MORE NEWS

From Our Sister Sites

FierceBiotech

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

FierceBiotech

In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.